📊 USNA Key Takeaways
Is Usana Health Sciences Inc. (USNA) a Good Investment?
USANA demonstrates severe profitability deterioration with net income plummeting 72.7% YoY despite 8.3% revenue growth, revealing critical operational inefficiencies. Despite maintaining a fortress balance sheet with $158.4M cash and zero debt, razor-thin margins (1.2% net, 4.0% operating) and abysmal returns (2.0% ROE, 1.4% ROA) indicate the company is failing to convert strong 78.3% gross margins into shareholder value.
Why Buy Usana Health Sciences Inc. Stock? USNA Key Strengths
- Strong gross margin of 78.3% indicates robust product pricing power and manufacturing efficiency
- Fortress balance sheet with $158.4M cash, zero long-term debt, and debt/equity of 0.00x provides financial flexibility and survival capability
- Revenue growth of 8.3% YoY demonstrates continued top-line expansion despite operational challenges
- Healthy liquidity with current ratio of 2.24x and quick ratio of 1.45x ensure short-term solvency
USNA Stock Risks: Usana Health Sciences Inc. Investment Risks
- Net income collapsed 72.7% YoY and EPS declined 73.5% YoY, signaling severe profitability crisis and operational breakdown
- Extremely poor returns on capital with ROE of 2.0% and ROA of 1.4% indicate value destruction and inefficient asset utilization
- Operating margin of only 4.0% despite 78.3% gross margin reveals massive operating expense burden (74.2% of revenue) or significant other charges
- Weak free cash flow generation at 0.9% FCF margin demonstrates poor cash conversion despite substantial asset base of $742.9M
Key Metrics to Watch
- Operating expense ratio and segment profitability trends to identify root cause of 72.7% earnings collapse
- Free cash flow and operating cash flow recovery path in next two quarters to assess cash generation improvement
- Return on equity trajectory and management's timeline to restore ROE to acceptable levels above 10%
- Gross margin sustainability and any deterioration in manufacturing or product mix profitability
Usana Health Sciences Inc. (USNA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 0.9% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.24x current ratio provides a solid financial cushion.
USNA Profit Margin, ROE & Profitability Analysis
USNA vs Materials Sector: How Usana Health Sciences Inc. Compares
How Usana Health Sciences Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Usana Health Sciences Inc. Stock Overvalued? USNA Valuation Analysis 2026
Based on fundamental analysis, Usana Health Sciences Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Usana Health Sciences Inc. Balance Sheet: USNA Debt, Cash & Liquidity
USNA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Usana Health Sciences Inc.'s revenue has declined by 22% over the 5-year period, indicating business contraction. The most recent EPS of $3.30 reflects profitable operations.
USNA Revenue Growth, EPS Growth & YoY Performance
USNA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $200.2M | -$6.5M | $-0.36 |
| Q2 2025 | $212.9M | $9.7M | $0.52 |
| Q1 2025 | $227.8M | $9.4M | $0.49 |
| Q3 2024 | $200.2M | $10.6M | $0.56 |
| Q2 2024 | $212.9M | $10.4M | $0.54 |
| Q1 2024 | $227.8M | $16.5M | $0.86 |
| Q3 2023 | $213.4M | $11.3M | $0.59 |
| Q2 2023 | $238.2M | $17.3M | $0.89 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Usana Health Sciences Inc. Dividends, Buybacks & Capital Allocation
USNA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Usana Health Sciences Inc. (CIK: 0000896264)
📋 Recent SEC Filings
❓ Frequently Asked Questions about USNA
What is the AI rating for USNA?
Usana Health Sciences Inc. (USNA) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are USNA's key strengths?
Claude: Strong gross margin of 78.3% indicates robust product pricing power and manufacturing efficiency. Fortress balance sheet with $158.4M cash, zero long-term debt, and debt/equity of 0.00x provides financial flexibility and survival capability.
What are the risks of investing in USNA?
Claude: Net income collapsed 72.7% YoY and EPS declined 73.5% YoY, signaling severe profitability crisis and operational breakdown. Extremely poor returns on capital with ROE of 2.0% and ROA of 1.4% indicate value destruction and inefficient asset utilization.
What is USNA's revenue and growth?
Usana Health Sciences Inc. reported revenue of $925.3M.
Does USNA pay dividends?
Usana Health Sciences Inc. does not currently pay dividends.
Where can I find USNA SEC filings?
Official SEC filings for Usana Health Sciences Inc. (CIK: 0000896264) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is USNA's EPS?
Usana Health Sciences Inc. has a diluted EPS of $0.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is USNA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Usana Health Sciences Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is USNA stock overvalued or undervalued?
Valuation metrics for USNA: ROE of 2.0% (sector avg: 14%), net margin of 1.2% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy USNA stock in 2026?
Our dual AI analysis gives Usana Health Sciences Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is USNA's free cash flow?
Usana Health Sciences Inc.'s operating cash flow is $22.3M, with capital expenditures of $13.8M. FCF margin is 0.9%.
How does USNA compare to other Materials stocks?
Vs Materials sector averages: Net margin 1.2% (avg: 10%), ROE 2.0% (avg: 14%), current ratio 2.24 (avg: 1.6).